9 Meters Biopharma, Inc. financial data

Location
4509 Creedmoor Road, Suite 600, Raleigh, NC
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2023 - May 15, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 134 % -80.5%
Debt-to-equity 267 % +1450%
Return On Equity -585 % -520%
Return On Assets -159 % -98%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.3M shares -94.4%
Common Stock, Shares, Outstanding 14.3M shares -94.4%
Common Stock, Value, Issued 1.43K USD -94.4%
Weighted Average Number of Shares Outstanding, Basic 13.6M shares +5.27%
Weighted Average Number of Shares Outstanding, Diluted 13.6M shares +5.27%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 11M USD +5.28%
Operating Income (Loss) -43.4M USD -1.67%
Nonoperating Income (Expense) -2.84M USD -10627%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -46.3M USD -8.39%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -46.3M USD -8.39%
Earnings Per Share, Basic -4 USD/shares +9.28%
Earnings Per Share, Diluted -4 USD/shares +9.28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.94M USD -81.4%
Assets, Current 9.2M USD -76.5%
Property, Plant and Equipment, Net 9.08K USD -47.5%
Operating Lease, Right-of-Use Asset 97.7K USD -36.4%
Other Assets, Noncurrent 8.98K USD +60.9%
Assets 9.31M USD -76.3%
Accounts Payable, Current 4.23M USD +121%
Employee-related Liabilities, Current 1.57M USD +37%
Accrued Liabilities, Current 5.76M USD -7.97%
Liabilities, Current 15.6M USD +89.4%
Operating Lease, Liability, Noncurrent 34.8K USD -64.7%
Liabilities 15.6M USD +87.6%
Retained Earnings (Accumulated Deficit) -226M USD -25.7%
Stockholders' Equity Attributable to Parent -6.3M USD -120%
Liabilities and Equity 9.31M USD -76.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.75M USD -0.01%
Net Cash Provided by (Used in) Financing Activities -12.3M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 550M shares 0%
Common Stock, Shares, Issued 14.3M shares -94.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -22M USD -126%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.62M USD -79.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 174K USD
Operating Lease, Liability 98.4K USD -36.5%
Depreciation 1.33K USD -18.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 108K USD -40%
Operating Lease, Liability, Current 63.6K USD +12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 54K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 54K USD -25%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.61K USD -61.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 100K USD 0%
Additional Paid in Capital 220M USD +4.3%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 3.99M USD +48.6%
Interest Expense 3.42M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%